Filing Details

Accession Number:
0001209191-23-018721
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-03-14 20:39:33
Reporting Period:
2023-03-13
Accepted Time:
2023-03-14 20:39:33
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1640455 Jounce Therapeutics Inc. JNCE () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1178579 C Kevin Tang 4747 Executive Drive, Suite 210
San Diego CA 92121
No No Yes No
1191935 Tang Capital Partners Lp 4747 Executive Drive
Suite 210
San Diego CA 92121
No No Yes No
1232621 Tang Capital Management Llc 4747 Executive Drive
Suite 210
San Diego CA 92121
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-03-13 65,701 $0.99 5,279,801 No 4 P Indirect By LP
Common Stock Acquisiton 2023-03-14 20,286 $1.02 5,300,087 No 4 P Indirect By LP
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Indirect By LP
No 4 P Indirect By LP
Footnotes
  1. The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $0.98 to $1.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 herein.
  2. The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
  3. The price reported is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $1.00 to $1.02.